These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 12038786)

  • 1. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model.
    Nicolaisen EM; Kristensen H; Kristensen A; Hedner U
    Thromb Haemost; 2002 May; 87(5):836-9. PubMed ID: 12038786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury.
    Söderström T; Hedner U; Arnljots B
    J Vasc Surg; 2001 May; 33(5):1072-9. PubMed ID: 11331851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats.
    Sommer C; Norbert Jørgensen P; Salanti Z; Clausen JT; Jensen LB
    Thromb Haemost; 2007 Oct; 98(4):721-5. PubMed ID: 17938793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.
    Petersen LC; Nørby PL; Branner S; Sørensen BB; Elm T; Stennicke HR; Persson E; Bjørn SE
    Thromb Res; 2005; 116(1):75-85. PubMed ID: 15850611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant factor VIIa in the rat--a comparison of bio-, immuno- and isotope assays.
    Thomsen MK; Diness V; Nilsson P; Rasmussen SN; Taylor T; Hedner U
    Thromb Haemost; 1993 Sep; 70(3):458-64. PubMed ID: 8259549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study.
    Lev EI; Marmur JD; Zdravkovic M; Osende JI; Robbins J; Delfin JA; Richard M; Erhardtsen E; Thomsen MS; Lincoff AM; Badimon JJ
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1036-41. PubMed ID: 12067917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer.
    Zerbib P; Grimonprez A; Corseaux D; Mouquet F; Nunes B; Petersen LC; Susen S; Ung A; Hebbar M; Pruvot FR; Chambon JP; Jude B
    J Surg Res; 2009 May; 153(2):239-45. PubMed ID: 19062044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-thrombotic and haemorrhagic effects of active site-inhibited factor VIIa in rats.
    Ghrib F; Léger P; Ezban M; Kristensen A; Cambus J; Boneu B
    Br J Haematol; 2001 Feb; 112(2):506-12. PubMed ID: 11167855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
    Yatuv R; Dayan I; Carmel-Goren L; Robinson M; Aviv I; Goldenberg-Furmanov M; Baru M
    Haemophilia; 2008 May; 14(3):476-83. PubMed ID: 18393980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.
    Jilma B; Marsik C; Mayr F; Graninger MT; Taylor FB; Ribel MC; Erhardtsen E; Handler S; Eichler HG
    Clin Pharmacol Ther; 2002 Oct; 72(4):403-10. PubMed ID: 12386642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor.
    Carlsson K; Persson E; Carlsson U; Svensson M
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1111-6. PubMed ID: 16970919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.
    Holst J; Kristensen AT; Kristensen HI; Ezban M; Hedner U
    Eur J Vasc Endovasc Surg; 1998 Jun; 15(6):515-20. PubMed ID: 9659887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
    Erhardtsen E; Nilsson P; Johannessen M; Thomsen MS
    J Clin Pharmacol; 2001 Aug; 41(8):880-5. PubMed ID: 11504276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local application of FFR-rFVIIa reduces thrombus formation at arterial anastomosis in rats.
    Sørensen HB; Kristensen AT; Ravn HB; Fuglsang J; Hjortdal VE
    Microsurgery; 1999; 19(8):369-73. PubMed ID: 10594911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIIa induced release of von Willebrand factor from human umbilical vein endothelial cells by a tyrosine kinase dependent pathway.
    Brown SA; Bowen DJ; Hallett MB; Giddings JC; Collins PW
    Thromb Haemost; 2002 Jun; 87(6):1057-61. PubMed ID: 12083486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: insights into mechanism of assembly/disassembly from tissue factor.
    Stone MD; Harvey SB; Martinez MB; Bach RR; Nelsestuen GL
    Biochemistry; 2005 Apr; 44(16):6321-30. PubMed ID: 15835921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation.
    Cirillo P; Calì G; Golino P; Calabrò P; Forte L; De Rosa S; Pacileo M; Ragni M; Scopacasa F; Nitsch L; Chiariello M
    Circulation; 2004 Jun; 109(23):2911-6. PubMed ID: 15173027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.
    Dargaud Y; Bordet JC; Trzeciak MC; Vinciguerra C; Negrier C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR20. PubMed ID: 16785139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.